Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer
Open Access
- 1 November 2018
- journal article
- research article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 10, 6039-6047
Abstract
Background: Small cell lung cancer (SCLC) is typically categorized according to disease extent as limited or extensive, and utility of the 8th TNM classification, recommended for lung cancer staging, which demonstrates a strong association with non-small-cell lung cancer (NSCLC) management, remains unclear. Methods: This retrospective study included 277 consecutive SCLC patients treated at a single institution between 2008 and 2016. Results: According to the currently used two-stage system, 186 (65.7%) of the patients were classified as having extensive disease (ED)-SCLC. Among the ED-SCLC patients, ten (5.3%), 38 (20.4%), 32 (17.2%), and 106 (57.0%) were categorized into stages M0, M1a, M1b, and M1c, respectively, according to the 8th TNM classification. There was a significant difference in overall survival based on the M descriptors: 15.8 (95% CI 9.4–22.2) months in the M1b group vs 7.3 (95% CI 5.7–8.9) months in the M1c group (PPConclusion: The 8th TNM classification has a prognostic value in SCLC. Similarly to NSCLC, treatment approaches should be considered on the basis of the 8th TNM classification, especially stage IVA separate from stage IVB in ED-SCLC patients.Keywords
This publication has 30 references indexed in Scilit:
- Novel Insights of Oligometastases and Oligo-Recurrence and Review of the LiteraturePulmonary Medicine, 2012
- The New Lung Cancer Staging SystemChest, 2009
- Prognostic factors differ by tumor stage for small cell lung cancerCancer, 2009
- Limited-Stage Small-Cell Lung Cancer: The Current Status of Combined-Modality TherapyJournal of Clinical Oncology, 2007
- Prophylactic Cranial Irradiation in Extensive Small-Cell Lung CancerNew England Journal of Medicine, 2007
- Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results DatabaseJournal of Clinical Oncology, 2006
- Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Time Between the First Day of Chemotherapy and the Last Day of Chest Radiation Is the Most Important Predictor of Survival in Limited-Disease Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastasesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung CancerNew England Journal of Medicine, 2002